Scot Ebbinghaus, MD, Hematology, Philadelphia, PA, Fox Chase Cancer Center-American Oncologic Hospital

ScotW.EbbinghausMD

Hematology Philadelphia, PA

Hematologic Oncology

Physician

Dr. Ebbinghaus is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ebbinghaus' full profile

Already have an account?

  • Office

    333 Cottman Avenue
    Fox Chase Cancer Cenetr
    Philadelphia, PA 19111
    Phone(215) 728-6900
    Fax(215) 728-3639
  • Is this information wrong?

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFELLOWSHIP
  • University of Alabama Medical Center
    University of Alabama Medical CenterRESIDENCY
  • University of Missouri - Kansas City School of Medicine
    University of Missouri - Kansas City School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2007 - 2020
  • AZ State Medical License
    AZ State Medical License 2000 - 2009
  • AL State Medical License
    AL State Medical License 1990 - 2007
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018

Press Mentions

  • FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients with Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
    FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients with Von Hippel-Lindau Disease- Associated Renal Cell CarcinomaJuly 29, 2020
  • Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with Von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
    Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with Von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell CarcinomaMay 13, 2020
  • Merck Builds Case for Six-Week Keytruda Dosing as FDA Starts Review
    Merck Builds Case for Six-Week Keytruda Dosing as FDA Starts ReviewApril 27, 2020
  • Join now to see all

Grant Support

  • Site Specific Alkylation Of The Her2/Neu PromoterNational Cancer Institute2002–2004
  • Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute2000–2002
  • Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute1998–2000
  • Triplex Based Gene Therapy Of Breast And Ovarian CancerNational Cancer Institute1996–1998

Hospital Affiliations